Why is AstraZeneca stock down today?

Traders Union
All News
Financial News
Astrazeneca slides 8.74% after trial miss

Highlights

AstraZeneca lost approximately £19 billion in market value after its Wainua drug missed key Phase III trial endpoints for transthyretin amyloid cardiomyopathy.
The company terminated its HELIOS rare disease trial without impact to significant revenue streams and announced a $2.1 billion licensing deal with Sino Biopharmaceutical.
AstraZeneca trades below crucial moving averages with bearish technical momentum, facing consolidation between GBX12,695 and GBX14,398 over the near term.

Market capitalization wiped out as trial miss and study halt shake sentiment

AstraZeneca’s shares saw heightened volatility following the company’s announcement that its Wainua (eplontersen) drug did not meet endpoints in a Phase III trial for transthyretin amyloid cardiomyopathy, leading to an estimated £19 billion loss in market capitalization. The company also halted its HELIOS rare disease study, though this was not linked to revenue-generating assets. Additional company activity included a new licensing deal with Sino Biopharmaceutical valued up to $2.1 billion and an officer share award, alongside ongoing partnership initiatives.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca in a precarious position following the Wainua Phase III trial failure and the corresponding £19 billion market cap loss. He notes that the multiple moving average breaches signal broad technical weakness, while sentiment remains negative amid heightened volatility and failed drug development milestones. Kharitonov is skeptical of any short-term recovery, especially as momentum and trend signals are sharply mixed but skewed toward sellers. He points to the risk of further downside if support at GBX12,695 fails, reinforcing a need for defensive positioning. "Given the critical news backdrop and technical breakdowns, I warn investors against chasing any rebounds in AstraZeneca at this stage."

Viktoras Karapetjanc, expert at Traders Union, highlights AstraZeneca’s strong institutional profile and dynamic deal-making despite recent clinical setbacks. He believes the licensing partnership with Sino Biopharmaceutical marks a strategic advance, with diversified revenue streams buffering near-term volatility. Karapetjanc maintains that AstraZeneca’s global pipeline and macro positioning support a bullish structure, and sees the current correction as an opportunity for forward-thinking investors. "With robust fundamentals and new partnerships, I expect the market to reward AstraZeneca’s innovation over the coming quarters."

Parshwa Turakhiya, analyst, interprets the recent drop in AstraZeneca as a sentiment-driven reaction amplified by technical gaps and mixed momentum signals. He notes price action is caught between key resistance and support levels, with buyers stepping in intraday despite bearish trends. Turakhiya believes short-term traders should monitor GBX13,106 and GBX12,695 closely for breakout setups, as volatility offers opportunity both ways. "I see rangebound swings favoring nimble strategies and urge close attention to momentum divergences and news catalysts."

Technical pressure intensifies as mixed signals contrast with resistance test

AstraZeneca is trading below the 20-day (GBX13,821), 50-day (GBX13,731), and 200-day (GBX13,768) moving averages, signalling persistent downward pressure across short-, medium-, and long-term horizons. The stock faces immediate resistance at GBX13,106 (near-term ceiling) and support at GBX12,695 (near-term floor), with the Ichimoku Kijun at GBX13,179 also acting as resistance. The medium- and long-term trend context remains bearish. Momentum signals present a mixed picture: MACD points to potential upside, but Average Directional Index (ADX) and Hull Moving Average (HMA) both indicate ongoing selling pressure. Relative Strength Index (RSI) and Commodity Channel Index (CCI) are flashing 'Buy', but Stochastic RSI and ADX both forecast 'Sell', and Bull/Bear Power (BBP) shows that buyers dominate intraday, currently at overbought levels. The stock last traded at GBX12,996, down GBX1,244 or 8.74% for the day, following a downside gap of GBX1,852 (13.01%). Price action is near the daily high, with intraday volatility at 5.80%. The intraday tone is characterized by early weakness followed by a rebound toward session highs, producing a divergence among momentum indicators.

Earlier, analysts noted that AstraZeneca shares faced sustained selling pressure and heightened volatility following the failure of a key drug trial and a major licensing deal. The latest developments reinforce this bearish outlook, with traders now watching for a potential shift in momentum should the stock decisively break above or below its defined resistance at GBX13,106 or support at GBX12,695.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.